Clinical Trials Browser

NCT07574541 2026-05-27

Multitargeted Recombinant Ad5 PSA/MUC-1/Brachyury-Based Immunotherapy (TriAdeno) Vaccine With IL-15 Superagonist N-803 in Participants With Clinically Localized Prostate Cancer Undergoing Active Surveillance

Adenocarcinoma, Carcinoma, Neoplasms, Neoplasms by Histologic Type, Neoplasms, Glandular and Epithelial, Prostatic Neoplasms

NCT07587814 2026-05-14

COCORIVO

Phase NA Not yet recruiting

100 enrolled

Genitourinary

Carcinoma, Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant

NCT07156227 2026-05-13

Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for Recurrent Head and Neck Squamous Cell Carcinoma

Phase 1 Not yet recruiting

39 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT07231809 2026-05-06

HIVEC

Phase NA Not yet recruiting

50 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma

NCT07281768 2026-05-06

Capecitabine/Oxaliplatin Chemotherapy and Cemiplimab With or Without Fianlimab or REGN7075 in Locally Advanced Rectal Cancer

Phase 2 Not yet recruiting

66 enrolled

Gastrointestinal

Adenocarcinoma, Carcinoma, Rectal Neoplasms, Colorectal Neoplasms

NCT07430202 2026-05-06

A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)

Phase 1 Not yet recruiting

27 enrolled

Gastrointestinal

Fibrolamellar hepatocellular carcinoma, Carcinoma, Liver Neoplasms

NCT07441681 2026-05-04

Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive Cisplatin

Phase 3 Not yet recruiting

454 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT07538193 2026-04-20

Iparomlimab and Tuvonralimab Plus Chemotherapy Before Surgery for Stage III Lung Cancer

Phase NA Not yet recruiting

28 enrolled

Thoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Lymphatic Metastasis

NCT07529262 2026-04-14

AspiRe HCC

Phase 3 Not yet recruiting

890 enrolled

Carcinoma, Fibrosis, Liver Cirrhosis, Neoplasms

NCT07489066 2026-03-23

Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC

Phase 2 Not yet recruiting

120 enrolled

Thoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms

NCT07453706 2026-03-09

The Application of Sentire Surgical System Plus Patient Side Single Arm in Robotic Colorectal Surgery

Phase NA Not yet recruiting

12 enrolled

Tumor-Agnostic

Carcinoma

NCT07201012 2025-11-17

SMT-SL

Phase NA Not yet recruiting

150 enrolled

DermatologicGastrointestinal

Carcinoma, Carcinoma, Basal Cell, Carcinoma, Squamous Cell, Colorectal Neoplasms, Hereditary Nonpolyposis, Skin Neoplasms, Muir-Torre Syndrome

NCT07135882 2025-08-22

PRIME-Lung

Phase 3 Not yet recruiting

420 enrolled

Thoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06813079 2025-02-18

Using Tumor Models to Determine Treatments

Phase 2 Not yet recruiting

25 enrolled

Gastrointestinal

Carcinoma, Carcinoma, Pancreatic Ductal

NCT06794320 2025-01-27

Antibiotic Stewardship in Suspected Neutropenic Fever (ASTERIC Trial)

Phase NA Not yet recruiting

648 enrolled

Classical hematologyOther hematologic neoplasm

Carcinoma, Emergencies, Neoplasms, Hematologic Neoplasms, Febrile Neutropenia

NCT06551896 2024-08-13

Pemigatinib and Immune Checkpoint Inhibitor Treated FGFR1/2/3 Alteration Advanced Solid Tumor

Phase 2 Not yet recruiting

30 enrolled

BreastGastrointestinalGenitourinarySarcomaThoracic

Breast Neoplasms, Carcinoma, Carcinoma, Transitional Cell, Lung Neoplasms, Sarcoma, Stomach Neoplasms

NCT06112041 2023-11-01

The Prospective Clinical Study of Precision PRaG Therapy in Elderly Patients With Advanced Solid Malignant Tumors (PRaG9.0)

Phase 2 Not yet recruiting

29 enrolled

Tumor-Agnostic

Carcinoma

NCT05144100 2021-12-03

SCOPE

Phase 2/3 Not yet recruiting

498 enrolled

Tumor-Agnostic

Carcinoma